A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 6, 2025

Primary Completion Date

December 1, 2025

Study Completion Date

May 31, 2026

Conditions
Acute Myeloid Leukemia With FLT3/ITD Mutation
Interventions
DRUG

XY0206

12.5 mg/table,On the morning of the day of dosing , subjects received XY0206 tablets orally on an empty stomach.Each group of 15 subjects was randomly assigned in a 3:1:1 ratio, with 9 receiving XY0206, 3 receiving a placebo of XY0206, and 3 receiving moxifloxacin.Group A (XY0206 tablets: 37.5 mg; moxifloxacin : 400 mg; placebo: 37.5 mg);Group B(XY0206 tablets: 75 mg; moxifloxacin : 400 mg; placebo: 150mg);Group C(XY0206 tablets:150 mg; moxifloxacin : 400 mg; placebo: 150mg)

DRUG

Moxifloxacin (400 mg)

400mg,On the morning of the day of dosing , subjects received moxifloxacin orally on an empty stomach

OTHER

XY0206 Placebo

12.5mg/table,On the morning of the day of dosing, subjects received XY0206 placebo orally on an empty stomach.Each group of 15 subjects was randomly assigned in a 3:1:1 ratio, with 9 receiving XY0206, 3 receiving a placebo of XY0206, and 3 receiving moxifloxacin.Group A (XY0206 tablets: 37.5 mg; moxifloxacin : 400 mg; placebo: 37.5 mg);Group B(XY0206 tablets: 75 mg; moxifloxacin : 400 mg; placebo: 150mg);Group C(XY0206 tablets:150 mg; moxifloxacin : 400 mg; placebo: 150mg)

Trial Locations (1)

Unknown

RECRUITING

PKUCare Luzhong Hospital, Zibo

All Listed Sponsors
lead

Shijiazhuang Yiling Pharmaceutical Co. Ltd

INDUSTRY